Improving treatment for diabetic foot ulcers with a new hydrogel
Advancing Diabetic Foot Ulcer Treatment with Provasliex, a Controlled PDGF Release Hydrogel for Promoting Vascularization and Managing Overactive Inflammation
This study is testing a new gel that helps heal diabetic foot ulcers by slowly releasing a special growth factor, making it easier for people with diabetes to recover without needing to change their dressings as often.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gelsana Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project ID | NIH-11007010 on NIH RePORTER |
What this research studies
This research focuses on developing Provasliex GelTM, a hydrogel that releases platelet-derived growth factor (PDGF) in a controlled manner to enhance healing for diabetic foot ulcers. With diabetes affecting around 37 million people in the U.S., and a significant portion suffering from foot ulcers, this innovative approach aims to address the limitations of current treatments that often fail to manage inflammation effectively. By providing a steady supply of PDGF, the gel could potentially reduce the need for frequent dressing changes and improve overall healing outcomes for patients. The study will evaluate the gel's effectiveness in promoting vascularization and managing inflammation in diabetic wounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes who are experiencing foot ulcers or lower leg ulcerations.
Not a fit: Patients without diabetes or those who do not have diabetic foot ulcers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster healing of diabetic foot ulcers and a reduction in the need for amputations.
How similar studies have performed: Previous research has shown that controlled release of PDGF can improve wound healing, indicating a promising avenue for this approach.
Where this research is happening
Aurora, United States
- Gelsana Therapeutics, INC. — Aurora, United States (Active)
Researchers
- Principal investigator: Rocker, Adam — Gelsana Therapeutics, INC.
- Study coordinator: Rocker, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.